198 related articles for article (PubMed ID: 37517955)
1. Tumor-agnostic drug development in dMMR/MSI-H solid tumors.
Bhamidipati D; Subbiah V
Trends Cancer; 2023 Oct; 9(10):828-839. PubMed ID: 37517955
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
3. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
4. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
5. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.
Zhang Z; Cheng S; Gong J; Lu M; Zhou J; Zhang X; Li J; Shen L; Peng Z
Eur J Surg Oncol; 2020 Oct; 46(10 Pt B):e33-e39. PubMed ID: 32732092
[TBL] [Abstract][Full Text] [Related]
8. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
[TBL] [Abstract][Full Text] [Related]
9. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
10. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Geurts BS; Zeverijn LJ; van Berge Henegouwen JM; van der Wijngaart H; Hoes LR; de Wit GF; Spiekman IA; Battaglia TW; van Beek DM; Roepman P; Jansen AM; de Leng WW; Broeks A; Labots M; van Herpen CM; Gelderblom H; Verheul HM; Snaebjornsson P; Voest EE
J Pathol; 2024 Jul; 263(3):288-299. PubMed ID: 38747304
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
Front Immunol; 2022; 13():795972. PubMed ID: 35371084
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
13. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
15. Non-operative management after immune checkpoint inhibitors for early-stage, dMMR/MSI-H gastrointestinal cancers.
Fazio R; Audisio A; Daprà V; Conti C; Benhima N; Abbassi FZ; Assaf I; Hendlisz A; Sclafani F
Cancer Treat Rev; 2024 Jul; 128():102752. PubMed ID: 38772170
[TBL] [Abstract][Full Text] [Related]
16. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
17. Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series.
Zhou C; Jiang T; Xiao Y; Wang Q; Zeng Z; Cai P; Zhao Y; Zhao Z; Wu D; Lin H; Sun C; Zhang R; Xiao W; Gao Y
Front Immunol; 2021; 12():784336. PubMed ID: 34975873
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability: A 2024 update.
Yamamoto H; Watanabe Y; Arai H; Umemoto K; Tateishi K; Sunakawa Y
Cancer Sci; 2024 Jun; 115(6):1738-1748. PubMed ID: 38528657
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
[TBL] [Abstract][Full Text] [Related]
20. Controversies and management of deficient mismatch repair gastrointestinal cancers in the neoadjuvant setting.
Boutin M; Gill S
Ther Adv Med Oncol; 2023; 15():17588359231162577. PubMed ID: 37007634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
